Accelerate Diagnostics, Inc. (NASDAQ:AXDX - Get Free Report) CFO David Patience sold 13,296 shares of the stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $0.87, for a total value of $11,567.52. Following the completion of the transaction, the chief financial officer now directly owns 50,419 shares in the company, valued at approximately $43,864.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
David Patience also recently made the following trade(s):
- On Monday, February 26th, David Patience sold 350 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.96, for a total value of $336.00.
Accelerate Diagnostics Stock Up 3.5 %
NASDAQ AXDX opened at $0.89 on Thursday. The company has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $3.37. Accelerate Diagnostics, Inc. has a 12-month low of $0.83 and a 12-month high of $11.90. The firm has a market cap of $19.28 million, a price-to-earnings ratio of -0.18 and a beta of 0.52.
Analyst Ratings Changes
A number of research analysts recently commented on the company. Craig Hallum reduced their target price on Accelerate Diagnostics from $2.00 to $1.00 and set a "hold" rating on the stock in a research note on Monday, April 1st. William Blair restated an "outperform" rating on shares of Accelerate Diagnostics in a research report on Tuesday, April 2nd. Finally, StockNews.com assumed coverage on shares of Accelerate Diagnostics in a research report on Thursday, April 4th. They set a "hold" rating for the company.
He Is Giving Away Bitcoin
From Crypto Swap Profits | Ad
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
>> Register right here
Read Our Latest Stock Report on Accelerate Diagnostics
Institutional Trading of Accelerate Diagnostics
Several institutional investors have recently added to or reduced their stakes in AXDX. Griffin Asset Management Inc. boosted its holdings in shares of Accelerate Diagnostics by 3.0% during the fourth quarter. Griffin Asset Management Inc. now owns 1,219,724 shares of the medical research company's stock worth $4,781,000 after purchasing an additional 35,146 shares during the period. Tejara Capital Ltd purchased a new stake in shares of Accelerate Diagnostics during the third quarter worth about $78,000. Sonora Investment Management Group LLC purchased a new stake in shares of Accelerate Diagnostics during the third quarter worth about $63,000. TCI Wealth Advisors Inc. purchased a new stake in shares of Accelerate Diagnostics during the third quarter worth about $337,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Accelerate Diagnostics by 31.8% during the second quarter. Geode Capital Management LLC now owns 655,906 shares of the medical research company's stock worth $531,000 after purchasing an additional 158,383 shares during the period. 17.14% of the stock is currently owned by hedge funds and other institutional investors.
About Accelerate Diagnostics
(
Get Free Report)
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
